HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dial Plant Consolidation To Achieve $6 Mil. In Annual Savings

This article was originally published in The Tan Sheet

Executive Summary

Dial is predicting pre-tax savings of $6 mil. annually through plant consolidation efforts in the U.S. and Argentina, President and CEO Herbert Baum said during the Prudential Securities "Back-To-School" consumer products conference in Boston Sept. 5.

You may also be interested in...



Dial

Consumer products firm to record tax write-off of $200 mil. from sale of "troubled" Specialty Personal Care division to Hathi Group (Chicago), company announces Aug. 28. Dial, Coast soap marketer will focus on core brand growth, lowering operating costs as it continues to seek a buyer for remaining operations (1"The Tan Sheet" Aug. 6, In Brief)

Dial

Consumer product firm puts itself on selling block after board of directors determined it would be difficult to keep the company operating independently. Dial and Coast marketer had been considering divesting specialty brands, but believes sale of complete operation would be more tax-effective. Potential acquirers could be Kao Corp. (Japan), Unilever (UK/Holland) or Henkel (Germany)

Dial Complete Kills 10 Times More Germs Than Regular Soaps - CEO

Dial Complete antibacterial foaming hand wash will generate $25 mil. to $30 mil. in first-year sales following its 2001 introduction, Dial President & CEO Herbert Baum stated at an investor meeting in New York Sept. 21.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS131701

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel